Use of catechins for the treatment of FGFR-associated disorders of bone repair and bone formation
Catechins, particularly (-)-epicatechin, address FGFR-related bone disorders by improving bone repair and formation, increasing bone volume and reducing pseudarthrosis in subjects with FGFR-related bone disorders.
Patent Information
- Application Number
- JP2024536419
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-20
- Filing Date
- 2022-12-19
- Publication Date
- 2024-12-26
AI Technical Summary
FGFR-related bone repair and bone formation disorders, such as craniosynostosis and chondrodysplasia, are characterized by abnormal bone healing and impaired bone quality, particularly in unstable fractures, due to aberrant FGFR signaling, leading to conditions like pseudarthrosis and reduced bone volume.
Administration of therapeutically effective amounts of catechins, specifically (-)-epicatechin, to subjects with FGFR-related disorders to modulate FGFR signaling and enhance bone repair and formation, improving bone volume and quality.
Catechins, particularly (-)-epicatechin, demonstrate the ability to restore defective bone repair by increasing bone volume and reducing pseudarthrosis, enhancing bone healing in FGFR-related disorders.
Smart Images

Figure 2024547031000007 
Figure 2024547031000008 
Figure 2024547031000009
Abstract
Description
[Technical field]
[0001] Field of the invention: The present invention relates to methods and pharmaceutical compositions for the treatment of FGFR-associated bone repair and bone formation and quality disorders.
[0002] Background of the invention: Fibroblast growth factor receptors (FGFRs) are key genes involved in bone formation. Patients with craniosynostosis and chondrodysplasia, which are linked to FGFR gain-of-function mutations, exhibit craniofacial and mandibular malformations (Kolar JC 2017). FGFR2-related craniosynostosis (e.g., Crouzon, Apert, and Pfeiffer syndromes) are characterized by the presence of unilateral or bilateral coronal craniosynostosis, which involves the fusion of one or more cranial sutures, resulting in variable cranial malformations with hypertelorism, exophthalmos, midface hypoplasia, and mandibular prognathism. FGFR3-related craniosynostosis (e.g., Muenke and Crouzon syndromes and acanthosis nigricans) exhibit craniofacial anomalies, i.e., unilateral or bilateral coronal craniosynostosis, and midface hypoplasia. FGFR3-related chondrodysplasias, such as achondroplasia, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), and hypochondroplasia (HCH), are characterized by short limbs, skull base abnormalities, macrocephaly, hearing loss, midface hypoplasia, and mandibular prognathism. Maxillofacial and neurosurgery is indicated for these patients with craniosynostosis and chondrodysplasia to correct the craniofacial and cranial abnormalities. The bone healing process occurs in two different ways, depending on the mechanical stability. Healing of stable fractures occurs via membranous ossification. In contrast, healing of unstable fractures is under the control of endochondral ossification. In this case, a large cartilage template is formed in the gap between the fractured bone fragments, which is replaced by bone, bridging the two ends of the fracture.
[0003] Fracture healing is a complex process involving a cascade of cellular events, including initial bleeding and inflammation, recruitment and proliferation of mesenchymal cells, followed by formation of a cartilage callus, and gradual replacement of the cartilage callus with callus. A wide variety of growth factors / cytokines regulate skeletal development and homeostasis, and may also regulate fracture healing. Tyrosine kinase receptors (RTKs) are well known to play a role in bone repair. Among the tyrosine kinase receptors, FGFR3 regulates the formation of the cartilage callus and its replacement by bone. In a mouse model of chondrodysplasia (Fgfr Y367C / + ), FGFR3 gain-of-function mutations impair bone regeneration in unstable tibial fractures and induce a pseudarthrosis phenotype within the callus (Julien et al., 2020).
[0004] Understanding skeletal repair and bone formation is essential for the development of therapeutics that are intended to be used to improve bone healing after surgical osteotomy or traumatic fracture. The exact function of FGFR in mandibular formation and repair remains to be elucidated. In the maxillofacial skeleton, the mandible is the largest and strongest bone of the face, and the occurrence of abnormal growth is the cause of jaw-mandibular imbalance and subsequent dental occlusion abnormalities and perturbations in facial growth. Two ossification processes control the development of the mandible: 1) endochondral ossification regulates the formation of the mandibular condylar cartilage and Meckel's cartilage, and 2) membranous ossification controls the formation and elongation of the interosseous ramus.
[0005] To investigate abnormal FGF signaling during mandibular bone formation and repair, we used a mouse model of hypochondroplasia (Fgfr3 N534K / +) was studied. The hypochondroplasia mouse model displays the mandibulofacial features of hypochondroplasia, namely macrocephaly and mandibular prognathism. Unstable fractures of the mandibles of adult hypochondroplasia mice were performed and the formation of the callus repair was analyzed at different critical repair time points. Our data confirm that abnormal activation of FGFR3 signaling impairs bone formation and resorption, bone quality and bone repair processes in hypochondroplasia mandibles, characterized by the presence of pseudoarthrosis in many calluses. Interestingly, treatment with catechin, a phenolic compound isolated from Theobroma cacao, partially restores the repair of callus defects and increases bone volume / total volume without pseudoarthrosis.
[0006] Summary of the invention: The present invention relates to methods and pharmaceutical compositions for the treatment of FGFR-associated disorders of bone repair and bone formation and quality. In particular, the present invention is defined by the claims.
[0007] Detailed description of the invention: The present invention relates to a method for treating FGFR-associated bone repair and bone formation disorders in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one catechin.
[0008] The present invention also relates to a method of restoring repair of defective bone in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one catechin.
[0009] The term "subject" or "patient" as used herein refers to mammals, such as rodents, cats, dogs and primates. In particular, the subject according to the present invention is a human. In particular, the subject according to the present invention is an adult. In particular, the subject according to the present invention is a child, a teenager, or an elderly person. In some embodiments, the patient is under 15 years old. In some embodiments, the patient is under 10 years old. In some embodiments, the patient is under 7 years old. In some embodiments, the patient is under 5 years old. In some embodiments, the patient is under 3 years old. In some embodiments, the patient is an adult. In some embodiments, the subject is over 15 years old. In some embodiments, the subject is over 20 years old. In some embodiments, the subject is over 25 years old. In some embodiments, the subject is over 30 years old. In some embodiments, the subject is over 35 years old.
[0010] The term "bone" as used herein is a hard tissue that constitutes part of the skeleton in most vertebrates. Bones protect the various organs of the body, produce red and white blood cells, store minerals, provide structure and support for the body, and allow mobility. Bones come in a wide variety of shapes and sizes and have complex internal and external structures. They are light but strong and hard, and perform multiple functions. Bone tissue (osseous tissue) is a hard tissue that is a type of specialized connective tissue. It has a honeycomb-like matrix inside that helps give bones rigidity. Bone tissue consists of different types of bone cells. Osteoblasts and osteocytes are involved in the formation and mineralization of bone; osteoclasts are involved in the resorption of bone tissue. Modified (flattened) osteoblasts become lining cells that form a protective layer on the bone surface. The mineralized matrix of bone tissue has an organic component, mainly collagen, called ossein, and an inorganic component, bone mineral, which consists of various salts. Bone tissue is made up of two types of mineralized tissue: cortical bone and cancellous bone (also called trabecular). Other types of tissue found in bone include bone marrow, endosteum, periosteum, nerves, blood vessels, growth plate, and articular cartilage.
[0011] The terms "bone formation", "osteogenesis" or "ossification" as used herein relate to the bone formation process. After precursor cells form osteoblastic cell lines, they proceed in three developmental stages of cell differentiation called proliferation, matrix maturation, and mineralization. Based on their embryological origin, there are two types of ossification, called intramembranous ossification, which occurs in mesenchymal cells that directly differentiate into osteoblasts in the ossification center without prior cartilage formation, and endochondral ossification, in which bone tissue mineralization is first formed through the formation of cartilage. In intramembranous ossification, bone development occurs directly. In this process, mesenchymal cells proliferate into areas with high vascularization in the embryonic connective tissue in the formation of cell aggregation centers or primary ossification centers. The cells will synthesize bone matrix in the periphery and the mesenchymal cells will continue to differentiate into osteoblasts. Thereafter, the bone will be remodeled and replaced by mature lamellar bone. Endochondral ossification forms the primary ossification center and the cartilage is extended by the proliferation of chondrocytes and the deposition of cartilage matrix. After this formation, the chondrocytes in the central cartilage region begin to progress to hypertrophic chondrocytes as they mature. After the primary ossification center is formed, the medullary cavity begins to proliferate towards the epiphysis. Subsequent stages of endochondral ossification will then occur in several zones of the bone.
[0012] In some embodiments, treatments of the present invention improve bone healing following surgical osteotomy or traumatic fracture.
[0013] As used herein, the term "surgical osteotomy" refers to a procedure in which a surgeon removes or sometimes adds a wedge of bone near a damaged joint. This shifts weight from the area of damaged cartilage to the area with more or healthier cartilage. As used herein, the term "bone healing" or "fracture healing" or "bone repair" has its common meaning in the art and refers to the proliferative physiological process by which the body promotes the repair of a fracture. The bone healing process has three overlapping stages. 1. Inflammation begins immediately after fracture and continues for several days. A fracture causes bleeding into the area, inflammation and blood clotting at the fracture site. This provides the initial structural stability and framework for new bone production. 2. Bone formation begins when the blood clot formed by inflammation is replaced by fibrous tissue and cartilage (known as the soft callus). As healing progresses, the soft callus is replaced by hard bone (known as the hard callus), which can be seen on an x-ray several weeks after the fracture. 3. Bone remodeling, the final stage of bone healing, lasts for several months. In remodeling, bone continues to form and compact, returning to its original shape. In addition, blood circulation in the area improves. Once proper bone healing has occurred, weight bearing (e.g., standing or walking) drives bone remodeling.
[0014] In some embodiments, the subject suffers from a bone fracture. As used herein, the term "bone fracture" refers to a medical condition in which there is a partial or complete disruption in the continuity of a bone. In more severe cases, the bone may break into several fragments.
[0015] In some embodiments, at least one catechin of the present invention increases bone density or bone volume / total volume (BV / TV). As used herein, the term "bone density" or "bone volume / total volume" (BV / TV) is the amount of bone mineral in bone tissue.
[0016] In some embodiments, at least one catechin of the present invention can be used to treat osteoporosis.As used herein, the term "osteoporosis" refers to bone disease characterized by the deterioration of bone tissue / density, which causes bone to become very thin and fragile over time.
[0017] As used herein, the term "craniofacial abnormalities" refers to a diverse group of variations in the growth of the bones of the head and face. Anomaly is a medical term meaning "irregularity" or "different from normal." These abnormalities are present at birth (congenital) and come in many variations. Some are mild, while others are severe and require surgery.
[0018] As used herein, the term "craniosynostosis" refers to a condition in which one or more of the fibrous sutures in the skull of a young infant fuse prematurely by turning into bone (ossification), thereby altering the growth pattern of the skull. It may be associated with a growth abnormality of the facial skeleton known as facio-cranial-stenosis, or may even fall within the context of a polymorphic syndrome.
[0019] As used herein, the term "mandible," also known as the lower jaw or jawbone, is the largest, strongest, and lowest bone in the human facial skeleton. It forms the lower jaw and holds the lower teeth in place. The mandible lies below the maxilla. It is the only movable bone of the skull (overlooking the ossicles of the middle ear). It is connected to the temporal bone by the temporomandibular joint.
[0020] In some embodiments, the subject has or will have an FGFR-associated bone repair and bone formation disorder, hi some embodiments, the subject has a gain-of-function mutation in an FGFR.
[0021] As used herein, the term "FGFR-associated bone repair and bone formation and bone quality disorders" or "FGFR-associated bone repair and bone formation disorders" refers to defects in the process of bone repair and bone formation. FGFR-associated bone repair disorders refer to abnormal repair of bone.
[0022] The term "fibroblast growth factors (FGFs)" as used herein refers to a family of cell signaling proteins; they are involved in a wide variety of processes, most notably as essential components for normal development in animal cells. Any irregularity in their function results in a range of developmental abnormalities. These growth factors typically act as systemically or locally circulating molecules of extracellular origin that activate cell surface receptors. A defining property of FGFs is that they bind to the co-receptors heparin and heparin sulfate. Thus, some are trapped in the extracellular matrix of tissues containing heparin sulfate proteoglycans and are released locally upon injury or tissue remodeling.
[0023] The term "fibroblast growth factor receptor" (FGFR) as used herein refers to a receptor that binds to a member of the fibroblast growth factor (FGF) protein family. Some of these receptors are involved in pathologies. Distinct membrane-based FGFRs have been identified in vertebrates, all of which belong to the tyrosine kinase superfamily: FGFR1 (see also fibroblast growth factor receptor 1) (=CD331), FGFR2 (see also fibroblast growth factor receptor 2) (=CD332), FGFR3 (see also fibroblast growth factor receptor 3) (=CD333), FGFR4 (see also fibroblast growth factor receptor 4) (=CD334), FGFRL1 (see also fibroblast growth factor receptor-like 1) and FGFR6.
[0024] In some embodiments, the subject has a gain-of-function mutation in FGFR3.
[0025] As used herein, the terms "FGFR3", "FGFR3 tyrosine kinase receptor" and "FGFR3 receptor" are used synonymously throughout the specification and refer to all naturally occurring isoforms of FGFR3. An exemplary human amino acid sequence of FGFR3 is provided by SEQ ID NO:1. [ka]
[0026] As used herein, the terms "FGFR3 gain-of-function mutation," "constitutively active FGFR3 receptor mutant," "constitutively active FGFR3 mutant," or "FGFR3 mutant exhibiting constitutive activity" are used synonymously and refer to a mutant of the receptor that exhibits biological activity (i.e., triggers downstream signaling) and / or exhibits greater biological activity in the presence of an FGF ligand than the biological activity of the corresponding wild-type receptor. Constitutively active FGFR3 mutants according to the invention are in particular (residues numbered according to their position in the precursor of fibroblast growth factor receptor 3 isoform 1 (806 amino acids long)): a mutant in which the serine residue at position 84 has been replaced by a lysine (hereinafter designated S84L); a mutant in which the arginine residue at position 200 has been replaced by a cysteine (hereinafter designated R200C); a mutant in which the arginine residue at position 248 has been replaced by a cysteine (hereinafter designated R248C); a mutant in which the serine residue at position 249 has been replaced by a cysteine (hereinafter designated S249C); a mutant in which the proline residue at position 250 has been replaced by an arginine (hereinafter designated P250R); an asparagine residue at position 262 has been replaced by an arginine (hereinafter designated P250R); a mutant in which the residue is replaced by a histidine (hereinafter designated N262H); a mutant in which the glycine residue at position 268 is replaced by a cysteine (hereinafter designated G268C); a mutant in which the tyrosine residue at position 278 is replaced by a cysteine (hereinafter designated Y278C); a mutant in which the serine residue at position 279 is replaced by a cysteine (hereinafter designated S279C); a mutant in which the glycine residue at position 370 is replaced by a cysteine (hereinafter designated G370C); a mutant in which the serine residue at position 371 is replaced by a cysteine (hereinafter designated S371C); a mutant in which the tyrosine residue at position 373 is replaced by a cysteine (hereinafter designated Y373C);Mutants in which the glycine residue at position 380 has been replaced by arginine (hereinafter designated G380R); mutants in which the valine residue at position 381 has been replaced by glutamate (hereinafter designated V381E); mutants in which the alanine residue at position 391 has been replaced by glutamate (hereinafter designated A391E); mutants in which the asparagine residue at position 540 has been replaced by lysine (hereinafter designated N540K); mutants in which the stop codon has been eliminated due to a base substitution, in particular mutants in which the stop codon has been mutated in an arginine, cysteine, glycine, serine or tryptophan codon (hereinafter designated X807R, X807C, X807G, X807S and X807R, respectively). a mutant in which the lysine residue at position 650 is replaced by another residue, in particular methionine, glutamate, asparagine or glutamine (hereinafter designated K650M, K650E, K650N and K650Q); a mutant in which the methionine residue at position 528 is replaced by isoleucine (hereinafter designated M528I); a mutant in which the isoleucine residue at position 538 is replaced by valine (hereinafter designated I538V); a mutant in which the asparagine residue at position 540 is replaced by serine (hereinafter designated N540S); a mutant in which the asparagine residue at position 540 is replaced by threonine (hereinafter designated N540T). Typically, the constitutively active FGFR3 mutant according to the present invention is an N540K, K650N, K650Q, M528I, I538V, N540S, N540T or A391E mutant.
[0027] In some embodiments, the subject has an FGFR3-associated skeletal disease.
[0028] The term "FGFR3-associated skeletal disease" as used herein is intended to mean a bone disease caused by abnormally increased activation of FGFR3, in particular by expression of a mutant constitutively active FGFR3 receptor, in particular a mutant constitutively active FGFR3 receptor as described above.
[0029] In some embodiments, the FGFR3-related skeletal disease is preferably FGFR3-related chondrodysplasia and FGFR3-related craniosynostosis.
[0030] As used herein, "FGFR3-associated chondrodysplasia" includes, but is not limited to, short stature disorders such as hypochondroplasia (HCH), thanatophoric dysplasia (TD) type I, thanatophoric dysplasia type II, achondroplasia (ACH), and SADDAN (severe achondroplasia with developmental delay and acanthosis nigricans).
[0031] In particular, the FGFR3-related skeletal disease is short stature.
[0032] As used herein, the term "dwarfism" has its ordinary meaning in the art and refers to short stature resulting from genetic or medical conditions. Dwarfism is generally defined as an adult height of 147 cm or less.
[0033] In particular, an FGFR3-associated skeletal disease is hypochondroplasia (HCH).
[0034] As used herein, the term "hypoplasia achondroplasia" (HCH) has its common meaning in the art and relates to disproportionately short sutures, shortened limbs, and a head that appears large compared to the underdeveloped parts of the body.
[0035] In some embodiments, the FGFR3-associated chondrodysplasia is hypochondroplasia caused by expression of a constitutively active N540K, K650N, K650Q, M528I, I538V, N540S or N540T mutant of the FGFR3 receptor.
[0036] In particular, an FGFR3-related skeletal disease is achondroplasia (ACH).
[0037] As used herein, the term "achondroplasia" (ACH) has its common meaning in the art and relates to a genetic defect in which the hands and feet are short but the torso is typically of normal length, with an enlarged head and prominent forehead.
[0038] In particular, the FGFR3-related skeletal disease is thanatophoric dysplasia (TD).
[0039] As used herein, the term "thanatophoric dysplasia" (TD) has its common meaning in the art and relates to severe skeletal defects characterized by a disproportionately small rib cage, very short limbs, and excess skin folds on the limbs.
[0040] In some embodiments, the FGFR3-associated skeletal disease is FGFR3-associated craniosynostosis. In some embodiments, the FGFR3-associated craniosynostosis corresponds to a genetic or sporadic disease.
[0041] In particular, FGFR3-associated craniosynostosis is Muenke syndrome, which is caused by expression of a constitutively active mutant form of the FGFR3 receptor, P250R.
[0042] In particular, FGFR3-associated craniosynostosis is Crouzon syndrome with acanthosis nigricans (CAN), which is caused by expression of a constitutively active A391E mutant of the FGFR3 receptor.
[0043] As used herein, the term "craniosynostosis" has its common meaning in the art and relates to a condition in which one or more of the fibrous sutures of a subject's skull fuse prematurely by turning into bone (ossification), thereby altering the growth pattern of the skull. "Crouzon syndrome with acanthosis nigricans" (CAN) is a very rare form of craniosynostosis.
[0044] The term "acanthosis nigricans" as used herein refers to brown to black, poorly defined, velvety textured pigmentation of the skin.
[0045] In particular, the subject suffers from a gain-of-function mutation in FGFR2.
[0046] As used herein, "FGFR2," "FGFR2 tyrosine kinase receptor," and "FGFR2 receptor" are used synonymously throughout the specification and refer to all naturally occurring isoforms of FGFR2.
[0047] As used herein, the terms "gain-of-function mutation of FGFR2", "constitutively active FGFR2 receptor mutant", "constitutively active FGFR2 mutant" or "constitutively active FGFR2 mutant" are used synonymously and refer to mutants of said receptors that exhibit biological activity (i.e. trigger downstream signaling) and / or biological activity in the presence of FGF ligand that is higher than the biological activity of the corresponding wild-type receptor. The constitutively active FGFR2 mutants according to the present invention are particularly selected from the group consisting of (residues numbered according to their position in the precursor of fibroblast growth factor receptor 3 isoform 1 (806 amino acids long)). In particular, the mutations in FGFR2 include a mutant in FGFR2 in which the tryptophan residue at position 290 is replaced by a cysteine (hereinafter designated as W290C), a mutant in which the aspartic acid residue at position 321 is replaced by an alanine (hereinafter designated as D321A), a mutant in which the tyrosine residue at position 340 is replaced by a cysteine (hereinafter designated as Y340C), a mutant in which the cysteine residue at position 342 is replaced by an arginine (hereinafter designated as Y340C), and a mutant in which the tryptophan residue at position 290 is replaced by a cysteine (hereinafter designated as Y340C). These include a mutant in which the cysteine residue at position 342 is replaced by a serine (hereinafter designated C342S), a mutant in which the cysteine residue at position 342 is replaced by a tryptophan (hereinafter designated C342W), a mutant in which the asparagine residue at position 549 is replaced by a histidine (hereinafter designated N549H), and a mutant in which the lysine residue at position 641 is replaced by an arginine (hereinafter designated K641R). Several severe abnormalities in human skeletal development have been associated with the presence of mutations in fibroblast growth factor receptor 2, including Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Bear-Stevenson skin turnover syndrome, and Pfeiffer syndrome.Most, if not all, cases of Pfeiffer syndrome (PS) are also caused by de novo mutations in the fibroblast growth factor receptor 2 gene, which have recently been shown to disrupt one of the ironclad rules governing ligand specificity: two splice mutant forms of fibroblast growth factor receptor, FGFR2c and FGFR2b, have acquired the ability to bind and be activated by atypical FGF ligands. This loss of ligand specificity results in aberrant signaling, suggesting that the severe phenotypes of these disease syndromes result from ectopic ligand-dependent activation of fibroblast growth factor receptor 2.
[0048] In some embodiments, the subject has an FGFR2-related skeletal disease.
[0049] The term "FGFR2-related skeletal disease" as used herein is intended to mean a skeletal disease called craniosynostosis, which is caused by abnormally increased activation of FGFR2, in particular by expression of mutant constitutively active FGFR2 receptors, in particular by mutations of constitutively active FGFR2 receptors as described above. FGFR2-related skeletal diseases relate to Crouzon syndrome, Jackson-Weiss syndrome, Apert syndrome, craniosynostosis, Pfeiffer syndrome, acrosyndactyly type V, and Bear-Stevenson skin rotation syndrome.
[0050] The term "treatment" or "treating" as used herein refers to both prophylactic or preventative treatments, as well as curative and improving a patient's condition or disease-modifying treatments (including treatment of patients at risk of or suspected of having a disease, as well as patients who are ill or have been diagnosed with a disease or medical condition), including the suppression of clinical recurrence. Treatments may be administered to subjects with a medical disorder or who may eventually develop a disorder to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of the disorder or recurring disorder, or to extend the subject's survival beyond the expected survival in the absence of such treatment. By "therapeutic regimen" is meant a pattern of treatment of a disease, e.g., a dosing pattern used during therapy. A therapeutic regimen may include an induction regimen and a maintenance regimen. The phrase "induction regimen" or "induction period" refers to a therapeutic regimen (or a portion of a therapeutic regimen) used for the initial treatment of a disease. The general goal of an induction regimen is to provide a high level of drug to the patient during the initial period of the treatment regimen. An induction regimen may (partially or entirely) use a "loading regimen", which may involve administering a higher dose of drug than the physician would use during a maintenance regimen, administering a drug more frequently than the physician would administer during a maintenance regimen, or both. The phrase "maintenance regimen" or "maintenance period" refers to a treatment regimen (or a portion of a treatment regimen) that is used for the maintenance of a patient during disease treatment, for example, to keep the patient in remission for an extended period of time (months or years). A maintenance regimen may use continuous therapy (e.g., administering a drug at regular intervals, such as once a day, once a week, once a month, once a year, etc.) or intermittent therapy (e.g., intermittent treatment, intermittent treatment, treatment upon relapse, or treatment upon reaching a certain predetermined criterion (e.g., symptoms of disease, etc.).
[0051] The term "preventing" as used herein is intended to characterize a prophylactic method or process, the purpose of which is to delay or prevent the onset of the disorder or condition to which such term applies.
[0052] The term "expression" when used in the context of gene or nucleic acid expression refers to the conversion of the information contained in a gene into a gene product. A gene product may be the direct transcription product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA, or any other type of RNA) or a protein produced by translation of an mRNA (i.e., FGFR3).
[0053] As used herein, the term "catechin" refers to a compound having the general formula (I): [ka] Flavan-3-ol is a type of natural phenol and antioxidant.
[0054] Catechin is a secondary metabolite of plants and belongs to the flavan-3-ols (or simply flavanols), which are part of the flavonoid chemical family. Catechin has two benzene rings (called A-ring and B-ring) and a dihydropyran heterocycle (C-ring) with a hydroxyl group on C3. The A-ring resembles the resorcinol moiety, while the B-ring resembles the catechol moiety. There are two asymmetric centers on C2 and 3 of the molecule. Catechin therefore has four diastereoisomers: two of the isomers are in the trans configuration and are called catechin, and the other two are in the cis configuration and are called epicatechin. The most common catechin isomer is (+)-catechin. The other stereoisomers are (-)-catechin or ent-catechin. The most common epicatechin isomer is (-)-epicatechin (also known as L-epicatechin, epicatechol, (-)-epicatechol, 1-acacatechin, 1-epicatechol, epi-catechin, 2,3-cis-epicatechin, or (2R,3R)-(-)-epicatechin). Methods for producing, synthesizing, or extracting catechin are well known to those of skill in the art.
[0055] In some embodiments, the catechin isomer is (+)-catechin (2R,3S). As used herein, the term "(+)-catechin" has its ordinary meaning in the art and is represented by the following formula: [ka] has.
[0056] In some embodiments, the catechin isomer is (-)-catechin (2S,3R). As used herein, the term "(-)-catechin" has its ordinary meaning in the art and is represented by the following formula: [ka] has.
[0057] In some embodiments, the epicatechin isomer is (+)-epicatechin (2R,3S). As used herein, the term "(+)-epicatechin" has its ordinary meaning in the art and is represented by the following formula: [ka] has.
[0058] In some embodiments, the epicatechin isomer is (-)-epicatechin (2R,3R). As used herein, the term "(-)-epicatechin" has its general meaning in the art and refers to (2R,3R)-2-(3,4-dihydrophenyl)-3,4-dihydro-2H-chromene-3,5,7-triol and has the following formula: [ka] It has.
[0059] In some embodiments, the (-)-epicatechin is substantially pure (-)-epicatechin. The term "substantially pure" as used herein refers to the total absence or near complete absence of impurities, such as related substance impurities. For example, when a (-)-epicatechin composition is said to be substantially pure, there is no detectable related substance impurity, or if a single related substance impurity is detected, it is present in an amount of 0.1% by weight or less, or if multiple related substance impurities are detected, they are present in aggregates in an amount of 0.6% by weight or less. The substantially pure (-)-epicatechin according to the present invention can inhibit or eliminate the functional activation of downstream signaling pathways of FGFR3 in vivo and / or in vitro. Substantially pure (-)-epicatechin may inhibit functional activation of downstream signaling pathways of FGFR3 by at least about 10%, preferably at least about 20%, preferably at least about 30%, preferably at least about 40%, preferably at least about 50%, preferably at least about 70, 75 or 80%, more preferably 85, 90, 95 or 100%, or preferably at least about 300% or preferably at least about 500%.
[0060] In some embodiments, the subject is administered a pharmaceutical composition comprising a therapeutically effective amount of a catechin.
[0061] The term "administering" or "administration" as used herein refers to the act of injecting or otherwise physically delivering a substance (as it exists outside the body) (e.g., catechin) to a subject, for example, by oral delivery (e.g., via bottle treatment), mucosal, intradermal, intravenous, subcutaneous, intramuscular delivery, and / or any other physical delivery method described herein or known in the art. When a disease or a symptom thereof is treated, administration of the substance is typically performed after the onset of the disease or a symptom thereof. When a disease or a symptom thereof is prevented, administration of the substance is typically performed before the onset of the disease or a symptom thereof.
[0062] A "therapeutically effective amount" refers to an amount effective at a dosage and for a period of time necessary to achieve a desired therapeutic result. A therapeutically effective amount of a drug may vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of the drug to elicit a desired response in the individual. A therapeutically effective amount is also an amount in which any toxic or adverse effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects. The effective dose and dosage regimen for a drug depends on the disease or condition to be treated and can be determined by one of ordinary skill in the art. A physician of ordinary skill in the art can determine and prescribe the effective amount of the pharmaceutical composition required. For example, a physician can start a dose of a drug used in a pharmaceutical composition at a level lower than required to achieve a desired therapeutic effect, and gradually increase the dose until the desired effect is achieved. In general, an appropriate dose of a composition of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect according to a particular dosage regimen. Such an effective dose will generally depend on the factors described above. For example, a therapeutically effective amount for therapeutic use can be measured by its ability to stabilize the progression of a disease. One skilled in the art would be able to determine such amounts based on such factors as the subject's size, the severity of the subject's symptoms, and the particular composition or route of administration selected. An exemplary, non-limiting range for a therapeutically effective amount of a drug is about 0.1-100 mg / kg, such as about 0.1-50 mg / kg, such as about 0.1-20 mg / kg, such as about 0.1 mg-10 mg / kg, such as about 0.5, such as about 0.3, about 1, about 3 mg / kg, about 5 mg / kg, or about 8 mg / kg. Administration can be, for example, intravenous, intramuscular, intraperitoneal, or subcutaneous, and can be administered, for example, near the target site. The dosage regimen in the above methods of treatment and use is adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus can be administered, or several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. In some embodiments, the effectiveness of treatment is monitored, eg, at predetermined time points, during therapy.As a non-limiting example, the treatment according to the present invention may be carried out in an amount of about 0.1 to 100 mg / kg per day, e.g., 0.2, 0.5, 0.9, 1.0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90 or 100 mg / kg per day, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90 or 100 mg / kg per day, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90 or 1 , 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 days, or alternatively for at least one of the 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 weeks, or any combination thereof, a single or divided dose may be provided every 24, 12, 8, 6, 4 or 2 hours, or any combination thereof.
[0063] In some embodiments, the patient is administered a pharmaceutical composition comprising a therapeutically effective amount of catechin as an active pharmaceutical ingredient and at least one pharma- ceutically acceptable excipient.
[0064] As used herein, the terms "active drug substance" or "active ingredient" are used synonymously. As used herein, the term "pharmaceutical composition" refers to a composition described herein or a pharma- ceutically acceptable salt thereof, which comprises other substances, such as carriers and / or excipients. Pharmaceutical compositions as provided herein typically include a pharma- ceutically acceptable carrier.
[0065] As used herein, the term "pharmaceutical acceptable carrier" includes any and all solvents, diluents, or other liquid vehicles, dispersing or suspending aids, surfactants, isotonicity agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, and the like, as appropriate for the particular dosage form desired. Remington's Pharmaceutical Sciences, 16th Edition, E. W. Martin (Mack Publishing, Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutical compositions and known techniques for their preparation.
[0066] A pharma- ceutically acceptable carrier or excipient refers to any type of non-toxic solid, semi-solid, or liquid filler, diluent, encapsulant material, or formulation auxiliary. Typically, pharmaceutical compositions contain vehicles that are acceptable for injectable formulations. These may be, in particular, isotonic, sterile saline solutions (such as monosodium or disodium phosphate, sodium chloride, potassium chloride, calcium chloride, or magnesium chloride, or mixtures of such salts), or dried, in particular lyophilized compositions that allow reconstitution of an injectable solution upon addition of sterile water or saline, as the case may be. Pharmaceutical dosage forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil, or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the dosage form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. Sterile injectable solutions are prepared by incorporating the agent of the present invention in the required amount in a suitable solvent together with some other ingredients as listed above as required, followed by sterilization filtration.Generally, dispersions are prepared by incorporating various sterilized active ingredients into a sterile vehicle that contains a basic dispersion medium and other ingredients as listed above as required.In the case of sterile powders for the preparation of sterile injectable solutions, the preferred preparation method is vacuum drying and freeze-drying technology, which produces a powder of active ingredient and any additional desired ingredient from its solution that has been previously sterilized and filtered.
[0067] In some embodiments, the subject is administered a food composition comprising a therapeutically effective amount of catechins.
[0068] Typically, the food composition comprises or consists of a food product, food additive, food ingredient, functional food, medical food, dietary supplement, nutraceutical, nutritional supplement, or oral preparation that contains an effective amount of catechins (e.g., treatment with a bottle). In some embodiments, the food composition is selected from a complete food composition, a food supplement, a nutraceutical composition, and the like. The composition of the present invention may be used as a food ingredient and / or a feed ingredient. The food ingredient may be in a liquid or solid dosage form depending on the use and / or the mode of application and / or the mode of administration. The food composition of the present invention may be made using known methods, such as adding an effective amount of catechins to a food base. The food product, food additive, food ingredient, functional food, medical food, dietary supplement, nutraceutical, nutritional supplement, or oral preparation of the present invention may be solid, semi-solid, or liquid. It may be in the form of a food product or food supplement, such as a tablet, gel, powder, capsule, drink, bar, and the like. For example, the composition may be in the form of a powder packaged in a sachet, which can be dissolved in water, fruit juice, milk, or another beverage.
[0069] The term "food" as used herein refers to liquid (i.e. drink), solid, or semi-solid dietary compositions, especially compositions that are entirely food (food substitutes), that do not require additional nutritional intake or food supplement compositions. Food supplement compositions do not completely replace the intake of nutrients by other means. The terms "food product", "food additive", "food ingredient" or "feed ingredient" as used herein include preparations that are functional foods or foodstuffs or can be added as nutritional supplements to functional foods or foodstuffs. By "nutritional food" or "nutraceutical" or "functional food" we mean foodstuffs that contain ingredients that have a beneficial effect on health or can improve physiological functions. By "food supplement" we mean foodstuffs that have the purpose of completing a normal food diet. Food supplements are concentrated sources of nutrients or other substances that have nutritional or physiological effects when they are taken alone or in combination in small amounts. The term "functional food" as used herein summarizes foodstuffs and the corresponding products that have been recently developed, the importance of which is due to their value not only for nutrition and taste, but also for the substances of certain components. According to the invention, the medium and long-term maintenance and promotion of health is important. In this respect, non-therapeutic applications are preferred. However, the preventive aspects and promotion of health, as well as the dietary character of the products, are best revealed by the term functional foods. In many cases, these concern products that are increasingly accumulated through assortment and selection (as is the case in the present invention), purification, concentration, additions. They do not include isolated active substances, especially in tablet or pill form. Although there is no legal definition of functional foods, the majority of patients interested in this area agree that they are foods marketed as having a specific health effect beyond the basic nutritional effect. Thus, functional foods are ordinary foods that incorporate into them constituents or ingredients (such as those described herein) that confer a specific function on the food, for example a medical or physiological benefit other than a purely nutritional effect.
[0070] In some embodiments, the food composition is a beverage, which is a functional or therapeutic beverage, a thirst quenching beverage, or a normal beverage.For example, the composition of the present invention can be used in soft drinks, fruit juices, or beverages containing whey protein as a component, health teas, cocoa beverages, milk beverages, and lactobacillus beverages, yogurt and drinking yogurt, cheese, ice cream, shaved ice, and desserts, confectionery, biscuits, cakes, and cake mixes, snack foods, balanced foods and beverages, fruit fillings, care glazes, chocolate bread fillings, cheesecake flavored fillings, fruit flavored cake fillings, cake and donut icings, instant bread filling creams, fillings for cookies, ready-to-use bread fillings, reduced calorie fillings, adult nutritional beverages, acidified soy / juice beverages, aseptic / retort chocolate beverages, bar mixes, powdered beverages, calcium-fortified soy / plain and chocolate milk, calcium-fortified coffee beverages.
[0071] The food composition, including the food product, food additive, food ingredient, functional food, medical food, dietary supplement, nutraceutical, nutritional supplement, or oral preparation of the present invention, typically includes a carrier or vehicle. "Carrier" or "vehicle" refers to a substance suitable for administration, including any such substance known in the art, such as any liquid, gel, solvent, liquid diluent, solubilizer, etc., that is non-toxic and does not adversely interact with any of the components of the composition. Examples of nutritionally acceptable carriers include, for example, water, salt solution, alcohol, silicone, wax, yellow petrolatum, vegetable oil, polyethylene glycol, propylene glycol, liposome, sugar, gelatin, lactose, amylose, magnesium stearate, talc, surfactant, silicic acid, viscous paraffin, flavor oil, fatty acid monoglyceride and diglyceride, petroethral fatty acid ester, hydroxymethyl-cellulose, polyvinylpyrrolidone, etc. In some embodiments, the compositions comprising the food products, food additives, food ingredients, functional foods, medical foods, dietary supplements, nutraceuticals, nutritional supplements, or oral preparations of the present invention contain protective hydrocolloids (e.g., gums, proteins, modified starches), binders, film formers, encapsulating agents / materials, wall / shell materials, matrix compounds, coating agents, emulsifiers, surfactants, solubilizing agents (oils, fats, waxes, lecithin, etc.), adsorbents, carriers, fillers, co-complexes, dispersing agents, wetting agents, processing aids (solvents), flow agents, taste masking agents, bulking agents, gelling agents, gel forming agents, antioxidants, and antimicrobial agents. The compositions may also contain conventional pharmaceutical additives and adjuvants, excipients and diluents, including, but not limited to, water, gelatin of any origin, vegetable gums, lignin sulfonates, talc, sugars, starches, gum arabic, vegetable oils, polyalkylene glycols, flavorings, preservatives, stabilizers, emulsifiers, buffers, lubricants, coloring agents, wetting agents, fillers, etc. In all cases such additional ingredients will be selected with regard to their suitability for the intended recipient.
[0072] The present invention will be further illustrated by the following figures and examples, which should not, however, be construed as limiting the scope of the present invention in any way. [Brief description of the drawings]
[0073] [Figure 1A] Micro-computed tomography scan analysis of mandibles 14 days after fracture. Callus volume is unchanged in treated Fgfr3N534K / + compared to untreated Fgfr3N534K / +. Bone volume / total volume is increased in treated Fgfr3N534K / + mandibles. *p<0.05, **p<0.01, ***p<0.001. [Figure 1B] Micro-computed tomography scan analysis of mandibles 28 days after fracture. Callus volume is decreased in treated Fgfr3N534K / + compared to untreated Fgfr3N534K / +. Bone volume / total volume is increased in treated Fgfr3N534K / + mandibles. *p<0.05, **p<0.01, ***p<0.001. [Figure 1C] Repair grade on day 28.
[0074] Working Example: Definition: As used herein, "FGFR3 N534K / + The term "hypoplastogenesis" refers to a mouse model of hypochondroplasia. Mutant mice display clinical features of hypochondroplasia, with growth abnormalities, growth plate abnormalities, partial absence of synchondros, and lordosis. The bones of adult hypochondroplasia animals have reduced bone density and the bone structure has some characteristics of osteoporotic bone, with a higher risk of fracture at older ages.
[0075] As used herein, "FGFR3 Y367C / +The term "FGFR3" refers to a mouse model that recapitulates the human achondroplasia phenotype. Clinical features of achondroplasia (e.g. short stature associated with reduced size of the foramen magnum, mandibular hypoplasia, hearing impairment, disc abnormalities, abnormal proliferation and differentiation of chondrocytes, and impaired trophoblast formation) (Pannier et al. 2009, 2010, Mugniery et al. 2012, Di Rocco et al. 2014, Biosse Duplan et al. 2016, Komla Ebri et al. 2016, Martin et al. 2018) are also present. A385E / + The term relates to a mouse model of Crouzon syndrome with acanthosis nigricans in which memory defects were observed.
[0076] result I-chondrogenesis hypoplasia (Fgfr3 N534K / + ) Testing mandibular repair in a mouse model Mandibular bone repair in a mouse model of hypochondroplasia (Fgfr3 N534K / + The experiments were carried out in 6-week-old adult animals and the mice were euthanized at four key time points: during bone repair (10, 14 and 21 days after fracture) and at the end of the normal bone healing process, i.e. 28 days after fracture.
[0077] Vertical mandibular fractures, Fgfr3 N534K / + and Fgfr3 + / + This destabilizing mandibular fracture protocol was performed in the ascending ramus region of mice, allowing the analysis of the endochondral bone repair process. N534K / + and Fgfr3 + / + Four batches (n=100) of mandibular fractures were studied (days 10, 14, 21, and 28). Using immunolabeling for type II (proliferative cartilage), type X (hypertrophic cartilage), and type I (bone) collagen, we observed that endochondral processes were perturbed and we hypothesized that Fgfr3 + / + Compared with Fgfr3 N534K / +In the 14-mm thick chondrocyte-treated rats, we observed delayed cartilage resorption, a decrease in the size of the hypertrophied chondrocyte area, and abnormal bone formation within the repair callus. To complete these data, we performed a histomorphometric analysis of the callus using Alcian Blue / Picrosirius staining at 28 days (after fracture). We found that Fgfr3 N534K / + We observed the presence of pseudoarthrosis (fibrosis within the callus) in mice, whereas the inventors found that Fgfr3 + / + 100% of the bone was observed in the callus. Considering the quality of the newly formed bone on day 28, we defined 4 grades of repair and classified the mice according to their repair grade (1-4). Defective repair was due to the Fgfr3 + / + Compared with Fgfr3 N534K / + (data not shown).
[0078] To analyze bone microstructure, we performed micro-computed tomography scans. + / + Compared with Fgfr3 N534K / + We observed microstructural changes in callus formation from days 10 to 28 in mutants. Bone volume / total volume (BV / TV) was significantly decreased at days 10 (-23%, p<0.05), 14 (-14%, p<0.01), 21 (-14.9%, p<0.005), and 28 (-5.8%, p, 0.05) in mutants compared to controls (Figures 1A and 1B).
[0079] Here, we conclude that Fgfr3 gain of function impaired bone repair and quality in an unstable mandible fracture model in hypochondroplasia mice. We observed 1) bone formation with altered bone architecture, with some characteristics of osteoporotic bone, and 2) the formation of pseudoarthrosis within the callus, thus confirming that endochondral ossification is severely perturbed in the mandible.
[0080] II-Improvement of mandibular bone formation and repair using (-)-epicatechin therapeutic approach Current therapeutic approaches to combat aberrant FGF signaling are numerous and diverse, including epicatechin, which targets signaling pathways downstream of FGFR3 (Martin et al., 2020).
[0081] Hypochondroplasia mice (Fgfr3 N534K / + ) were treated with (-)-epicatechin (0.3 mg / kg, subcutaneously, three times a week) from day 0 (mandibular fracture) to day 14 or 28. Bone repair analysis was assessed by microcomputed tomography scanning on days 14 (Figure 1A) and 28 (Figure 1B) after fracture.
[0082] A significant decrease in callus volume is observed in treated hypochondroplasia mice (n=9) compared to untreated mice (n=14) at 28 days post-fracture (-39.8%, p<0.01). Bone volume / total volume is increased in treated hypochondroplasia mice (n=7) compared to untreated hypochondroplasia mice (n=7) at 14 days post-fracture (+19%, p<0.05) and in hypochondroplasia mice (n=9) compared to untreated hypochondroplasia mice (n=14) at 28 days post-fracture (+6.3%; p<0.05).
[0083] Gain-of-function mutations in FGFR3 disrupted bone formation, bone quality, and repair in a mandibular unstable fracture model. Callus is abnormal in hypochondroplasia mice as revealed by quantitative bone analysis by micro-computed tomography scanning. Bone volume / total volume is significantly reduced in hypochondroplasia mice compared to wild type.
[0084] Comparative analysis of mandibular bone repair in batches of mice (Fgfr3 + / + , Fgfr3 N534K / + , and Fgfr3 N534K / ++ (-)-epicatechin) highlighted the abnormal bone formation and repair in achondroplasia mice, and the beneficial effect of epicatechin treatment on mandibular bone repair. Complete bone healing (grade 1) was observed in 1 out of 9 mice. Restoration of bone continuity, but the presence of mild bone defects (grade 2), was observed in 6 out of 9 mice, and the presence of callus, but with partial bone discontinuity (grade 3), was observed in 2 out of 9 mice (Figure 1C). We did not observe pseudoarthrosis in treated achondroplasia mice 28 days after fracture. These results demonstrate the beneficial effect of (-)-epicatechin treatment.
[0085] conclusion Altogether, these data provide proof of concept that treatment with (-)-epicatechin improves mandibular bone formation and repair in the setting of FGFR3-associated chondrodysplasia.
[0086] References: Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into this disclosure.
Claims
1. A method of treating an FGFR3-associated bone repair and bone formation disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one catechin.
2. The method of claim 1 , wherein the subject is a child or an adult.
3. The method of claim 1, wherein said catechin is (+)-catechin.
4. The method of claim 1, wherein said catechin is (-)-catechin.
5. The method of claim 1, wherein said catechin is (+)-epicatechin.
6. The method of claim 1, wherein said catechin is (-)-epicatechin.
7. The method of claim 1 , wherein the subject has an FGFR gain-of-function mutation.
8. 8. The method of claim 7, wherein the FGFR gain-of-function mutation is an FGFR-associated skeletal disease.
9. 9. The method of claim 8, wherein the FGFR-associated skeletal disease is hypochondroplasia (HCH), achondroplasia (ACH), thanatophoric dysplasia (TD), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Muenke syndrome, Crouzon syndrome with acanthosis nigricans, dwarfism, or craniosynostosis.
10. 10. The method of claim 9, wherein the FGFR-associated skeletal disease is hypochondroplasia (HCH).
11. 10. The method of claim 9, wherein the FGFR3-associated skeletal disease is achondroplasia (ACH).
12. 10. The method of claim 9, wherein the FGFR3-associated skeletal disease is craniosynostosis.
13. 13. The method of claim 12, wherein the craniosynostosis is Crouzon syndrome with acanthosis nigricans (CAN).
14. 10. The method of claim 9, wherein the FGFR3-associated skeletal disease is Muenke syndrome.
15. 8. The method of claim 7, wherein the FGFR gain-of-function mutation is an FGFR2-associated skeletal disease.
16. 16. The method of claim 15, wherein the FGFR2-associated skeletal disease is Crouzon syndrome, Jackson-Weiss syndrome, Apert syndrome, craniosynostosis, Pfeiffer syndrome, acrosyndactyly type V, and Bear-Stevenson skin rotation syndrome.
17. The method of claim 1, wherein the subject is administered a pharmaceutical composition comprising a therapeutically effective amount of catechin as an active pharmaceutical ingredient and at least one pharma- ceutical acceptable excipient.
18. The method of claim 1 , wherein the subject is administered a food composition containing a therapeutically effective amount of catechins.
Citation Information
Patent Citations
Osteogenic promoter
JP2004161669A
Methods and pharmaceutical compositions for the treatment of FGFR3-associated chondrodysplasia
JP2021511379A
Compounds and compositions for treating muscle disorders
JP2021514380A
Methods and pharmaceutical compositions for the treatment of FGFR3-related cognitive deficit
WO2021250198A1
